ProC® Global Assay in the Evaluation of Women with History of Severe Preeclampsia or HELLP Syndrome

Abstract

Preeclampsia/HELLP syndrome has been associated with a high incidence of defects in the protein C pathway and increased anticardiolipin-antibodies/lupus anticoagulants. It is also apparent that thrombophilia is responsible for other pregnancy complications, such as recurrent spontaneous abortion, fetal growth restriction, intrauterine fetal death, and abruptio placentae. ProC® Global is a new global clotting assay designed to evaluate the abnormalities in the protein C anticoagulant pathway. It is based on the ability of endogenous activated protein C, generated by activation of protein C by Protac®, to prolong an activated partial thromboplastin time. A total of 61 patients with a history of severe preeclampsia or HELLP syndrome and 61 normal pregnant women (controls) were evaluated, 15 of whom had factor V Leiden mutation, 12 had protein C/S deficiency, 30 had a repeated lupus anticoagulants, and 27 increased anticardiolipin antibodies (ACA). All carriers of factor V Leiden mutation (N= 15) as well as all the patients with low activated protein C (APC) resistance ratio (N= 15) had a ProC® Global normalized ratio (NR) less than 0.80 (sensitivity 100%). Twenty-four patients positive for the lupus anticoagulants (LA) and 19 patients positive for ACA (> 5.0 IgG U/mL) had a ProC® Global NR less than 0.8, while six and eight, respectively, had a ProC® Global NR greater than 0.8 (sensitivity, 70%-80%). The detection of a reduced protein C/protein S activity (<70%) was low (sensitivity, 33%-44%). In 25 cases with pathologic ProC® Global results, a thrombophilic defect (protein S/LA/ACA without APC resistance) was diagnosed in 18 women; but in 7 cases, no known thrombophilic defect was present. ProC® Global is a new screening test to identify patients with defects of the protein C system and an activated clotting system in preeclampsia but cannot correctly cover each thrombophilic component.

Keywords

ProC-Global-Assay Severe preeclampsia HELLP syndrome

References

1. Clarke P , Brennand J , Conkie JA , McCall F , Greer IA , Walker ID . Activated protein C sensitivity, protein C, protein S, and coagulation in normal pregnancy. Thromb Haemost 1998;79:1166-1166.

2. Bick RL . Antiphospholipid thrombosis syndrome. Clin Appl Thromb/Hemost 2001;7:241-241.

3. Eldor A . Thrombophilia, thrombosis and pregnancy. Thromb Haemost 2001;86:104-104.

4. Kraus M . The anticougulant potential of the protein C system in hereditary and acquired thrombophilia: Pathomechanisms and new tools for assessing its clinical relevance. Semin Thromb Haemost 1998;24:337-337.

5. Sarig G , Lanir N , Hoffmann R , Brenner B . Protein C Global assay in the evalution of women with pregnancy loss. Thromb Haemost Suppl 2001;abstract P30-P34.

6. Bertina RM , Koeleman BPC , Koster F . Mutation in blood coagulation factor V associated with resistance to activated Protein C. Nature 1994;369:64-64.

7. Khamashta MA , Hughes GRV . Detection and importance of anticardiolipin antibodies. J Clin Pathol 1993;46:104-104.

8. Harris EN , Pierangeli SS . “Equivocal” antiphospholipid syndrome. JAutoimmunity 2000;15:81-81.

9. Hemostasis and Thrombosis Task Force . Lupus anticoagulant working party on behalf of the ICSH: Guidelines on testing for the lupus anticoagulant. J Clin Pathol 1991;44:858-858.

10.

10. Toulon P , Halbmeyer WM , Hafner G , Schmitt Y , Randgard B , Odpadlik M , Van den Eynden C , Wagner C . Screening for abnormalities of the protein C anticoagulant pathway using the PROC global assay. Results of a European multicenter evaluation. Blood Coag Fibrinol 2000;11:447-447.

11.

11. Toulon P , Adda A , Perez P . Sensitivity of the ProC® Global assay for protein C pathway abnormalities. Clinical experience in 899 unselected patients with venous thromboembolism. Thromb Res 2001;104:93-93.

12.

12. Dragoni F , Tormene D , Simioni P , Arcieri P , Avvisati G , Girolami A . ProC® Global: A new automated screening assay for the evaluation of total function of the protein C system. Clin Appl Thromb/Hemost 2001;714:351-351.

13.

13. Gemmati G , Serino ML , Tognazzo S , Ongaro A , Moratelli S , Gilli G , Forini E , De Mattei M , Scapoli GL . The reduced sensitivity of the ProC® Global test in protein S deficient subjects reflects a reduction in the associated thrombotic risk. Blood Coagul Fibrinol 2001;12:691-691.

14.

14. Robert AV , Aillaud MF , Eschwege V , Verdy E , Barthet MC , Morange PE , Juhan-Vague I . Screening for identified and unidentified protein C pathway defects by the agkistrodon contortrix venom test in consecutive patients. Am J Clin Pathol 1999;112:233-233.

15.

15. Robert A , Eschwege V , Hameg H , Drouet L , Aillaud MF . Anticoagulant response to agkistrodon contortrix venom (ACV test): A new global test to screen for defects in the anticoagulant protein C pathway. Thromb Haemost 1996;75:562-562.